Clinical Trial Update: Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intravenous high-dose ascorbate with gemcitabine and carboplatin for muscle-invasive bladder cancer; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Muscle-invasive Bladder Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Gemcitabine (Gemcitabine)
• Intravenous ascorbate (ascorbic acid)

Snippet

Sponsor: University of Kansas Medical Center | Conditions: Bladder Cancer | Phase 2 | Status: RECRUITING